Do analysts rate BGM or PMCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, BGM or PMCB?

Nuvilex has lower revenue, but higher earnings than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $37.92M 0.74 -$1.44M N/A N/A Nuvilex N/A N/A $30.66M -$1.12 N/A

Is BGM or PMCB more profitable?

Nuvilex's return on equity of 2.13% beat BGM Group's return on equity. Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Nuvilex N/A 2.13% 1.69%

Does the media refer more to BGM or PMCB?

In the previous week, BGM Group had 1 more articles in the media than Nuvilex. MarketBeat recorded 3 mentions for BGM Group and 2 mentions for Nuvilex. Nuvilex's average media sentiment score of 1.32 beat BGM Group's score of 0.30 indicating that Nuvilex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BGM Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvilex 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer KYNB or PMCB?

Kyntra Bio currently has a consensus target price of $32.50, suggesting a potential upside of 362.30%. Given Kyntra Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Kyntra Bio is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, KYNB or PMCB?

Kyntra Bio has higher revenue and earnings than Nuvilex. Nuvilex is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyntra Bio $7.44M 3.83 $183.45M $40.46 0.17 Nuvilex N/A N/A $30.66M -$1.12 N/A

Is KYNB or PMCB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Nuvilex's net margin of 0.00%. Nuvilex's return on equity of 2.13% beat Kyntra Bio's return on equity. Company Net Margins Return on Equity Return on Assets Kyntra Bio 2,199.13% N/A -36.71% Nuvilex N/A 2.13% 1.69%

Do analysts recommend PMCB or TAOX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PMCB or TAOX more profitable?

Nuvilex's return on equity of 2.13% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A 2.13% 1.69% Synaptogenix N/A -163.40% -133.47%

Do analysts recommend PMCB or BTAI?

BioXcel Therapeutics has a consensus target price of $11.00, indicating a potential upside of 1,197.94%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts rate GRDX or PMCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GRDX or PMCB more profitable?

Nuvilex's return on equity of 2.13% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -49.81% -11.02% Nuvilex N/A 2.13% 1.69%

Nuvilex (PMCB) Competitors

$0.60 0.00 (-0.78%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$0.61 +0.01 (+1.65%)

As of 07/24/2026 06:22 PM Eastern

Compare

PMCB vs. BGM, KYNB, TAOX, BTAI, and GRDX

Should you buy Nuvilex stock or one of its competitors? MarketBeat compares Nuvilex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvilex include BGM Group (BGM), Kyntra Bio (KYNB), Synaptogenix (TAOX), BioXcel Therapeutics (BTAI), and Entero Therapeutics (GRDX). These companies are all part of the "pharmaceutical products" industry.

How does Nuvilex compare to BGM Group?

BGM Group (NASDAQ:BGM) and Nuvilex (NASDAQ:PMCB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

In the previous week, BGM Group had 1 more articles in the media than Nuvilex. MarketBeat recorded 3 mentions for BGM Group and 2 mentions for Nuvilex. Nuvilex's average media sentiment score of 1.32 beat BGM Group's score of 0.30 indicating that Nuvilex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BGM Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvilex	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

34.2% of Nuvilex shares are held by institutional investors. 58.7% of BGM Group shares are held by company insiders. Comparatively, 11.0% of Nuvilex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BGM Group has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market. Comparatively, Nuvilex has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

Nuvilex's return on equity of 2.13% beat BGM Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Nuvilex	N/A	2.13%	1.69%

Nuvilex has lower revenue, but higher earnings than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$37.92M	0.74	-$1.44M	N/A	N/A
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Nuvilex beats BGM Group on 5 of the 9 factors compared between the two stocks.

How does Nuvilex compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and Nuvilex (NASDAQ:PMCB) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Kyntra Bio has a net margin of 2,199.13% compared to Nuvilex's net margin of 0.00%. Nuvilex's return on equity of 2.13% beat Kyntra Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-36.71%
Nuvilex	N/A	2.13%	1.69%

Kyntra Bio currently has a consensus target price of $32.50, suggesting a potential upside of 362.30%. Given Kyntra Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Kyntra Bio is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 34.2% of Nuvilex shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by company insiders. Comparatively, 11.0% of Nuvilex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kyntra Bio has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Nuvilex has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

In the previous week, Nuvilex had 1 more articles in the media than Kyntra Bio. MarketBeat recorded 2 mentions for Nuvilex and 1 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 1.87 beat Nuvilex's score of 1.32 indicating that Kyntra Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Kyntra Bio	Very Positive
Nuvilex	Positive

Kyntra Bio has higher revenue and earnings than Nuvilex. Nuvilex is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$7.44M	3.83	$183.45M	$40.46	0.17
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A

Summary

Kyntra Bio beats Nuvilex on 12 of the 16 factors compared between the two stocks.

How does Nuvilex compare to Synaptogenix?

Nuvilex (NASDAQ:PMCB) and Synaptogenix (NASDAQ:TAOX) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

Nuvilex's return on equity of 2.13% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	2.13%	1.69%
Synaptogenix	N/A	-163.40%	-133.47%

34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by company insiders. Comparatively, 2.7% of Synaptogenix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nuvilex has higher earnings, but lower revenue than Synaptogenix. Nuvilex is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A
Synaptogenix	$687.84K	35.74	-$28.74M	-$13.28	N/A

In the previous week, Nuvilex had 1 more articles in the media than Synaptogenix. MarketBeat recorded 2 mentions for Nuvilex and 1 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 1.87 beat Nuvilex's score of 1.32 indicating that Synaptogenix is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvilex	Positive
Synaptogenix	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuvilex has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

Summary

Nuvilex beats Synaptogenix on 7 of the 11 factors compared between the two stocks.

How does Nuvilex compare to BioXcel Therapeutics?

Nuvilex (NASDAQ:PMCB) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Nuvilex has higher earnings, but lower revenue than BioXcel Therapeutics. Nuvilex is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A
BioXcel Therapeutics	$680K	38.48	-$69.90M	-$5.75	N/A

Nuvilex has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. Nuvilex's return on equity of 2.13% beat BioXcel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	2.13%	1.69%
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%

Nuvilex has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

In the previous week, Nuvilex had 1 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 2 mentions for Nuvilex and 1 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 1.87 beat Nuvilex's score of 1.32 indicating that BioXcel Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvilex	Positive
BioXcel Therapeutics	Very Positive

BioXcel Therapeutics has a consensus target price of $11.00, indicating a potential upside of 1,197.94%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

34.2% of Nuvilex shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 11.0% of Nuvilex shares are held by insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Nuvilex beats BioXcel Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Nuvilex compare to Entero Therapeutics?

Entero Therapeutics (NASDAQ:GRDX) and Nuvilex (NASDAQ:PMCB) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

In the previous week, Nuvilex had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 2 mentions for Nuvilex and 1 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 1.87 beat Nuvilex's score of 1.32 indicating that Entero Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Entero Therapeutics	Very Positive
Nuvilex	Positive

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 34.2% of Nuvilex shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Comparatively, 11.0% of Nuvilex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Entero Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market. Comparatively, Nuvilex has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuvilex has lower revenue, but higher earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$74.46K	282.24	-$6.39M	-$1.88	N/A
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A

Nuvilex's return on equity of 2.13% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-49.81%	-11.02%
Nuvilex	N/A	2.13%	1.69%

Summary

Nuvilex beats Entero Therapeutics on 9 of the 12 factors compared between the two stocks.

Get Nuvilex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMCB vs. The Competition

Export

Metric	Nuvilex	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.49M	$3.06B	$6.86B	$12.25B
Dividend Yield	N/A	2.07%	2.67%	9.79%
P/E Ratio	-0.54	20.29	27.14	23.64
Price / Sales	N/A	485.21	517.01	89.03
Price / Cash	N/A	27.62	50.54	59.64
Price / Book	0.08	4.13	10.28	6.07
Net Income	$30.66M	$65.94M	$3.60B	$331.99M
7 Day Performance	-5.20%	-4.16%	-1.27%	-0.63%
1 Month Performance	-20.91%	-3.76%	-0.37%	-2.00%
1 Year Performance	-37.16%	9.94%	18.30%	13.62%

Nuvilex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMCB Nuvilex	0.8127 of 5 stars	$0.60 -0.8%	N/A	-36.8%	$6.49M	N/A	N/A	4	Positive News
BGM BGM Group	0.4327 of 5 stars	$0.29 -6.1%	N/A	-97.4%	$30.24M	$25.10M	N/A	298	News Coverage Short Interest Increase Gap Up
KYNB Kyntra Bio	4.1416 of 5 stars	$7.39 +2.5%	$32.50 +339.8%	N/A	$29.19M	$6.44M	0.18	570	Positive News
TAOX Synaptogenix	0.7063 of 5 stars	$3.54 -7.6%	N/A	N/A	$28.62M	$300K	N/A	4	Positive News
BTAI BioXcel Therapeutics	2.7689 of 5 stars	$0.87 -5.6%	$11.00 +1,164.2%	-51.0%	$28.45M	$640K	N/A	90	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMCB) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvilex (PMCB) Competitors

PMCB vs. BGM, KYNB, TAOX, BTAI, and GRDX

How does Nuvilex compare to BGM Group?

Summary

How does Nuvilex compare to Kyntra Bio?

Summary

How does Nuvilex compare to Synaptogenix?

Summary

How does Nuvilex compare to BioXcel Therapeutics?

Summary

How does Nuvilex compare to Entero Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB vs. The Competition

Nuvilex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvilex (PMCB) Competitors

PMCB vs. BGM, KYNB, TAOX, BTAI, and GRDX

How does Nuvilex compare to BGM Group?

Does the media refer more to BGM or PMCB?

Do insiders and institutionals believe in BGM or PMCB?

Which has more volatility & risk, BGM or PMCB?

Is BGM or PMCB more profitable?

Which has better valuation and earnings, BGM or PMCB?

Do analysts rate BGM or PMCB?

Summary

How does Nuvilex compare to Kyntra Bio?

Is KYNB or PMCB more profitable?

Do analysts prefer KYNB or PMCB?

Do institutionals & insiders hold more shares of KYNB or PMCB?

Which has more volatility and risk, KYNB or PMCB?

Does the media favor KYNB or PMCB?

Which has higher earnings & valuation, KYNB or PMCB?

Summary

How does Nuvilex compare to Synaptogenix?

Is PMCB or TAOX more profitable?

Do institutionals & insiders have more ownership in PMCB or TAOX?

Which has preferable earnings & valuation, PMCB or TAOX?

Does the media prefer PMCB or TAOX?

Do analysts recommend PMCB or TAOX?

Which has more risk & volatility, PMCB or TAOX?

Summary

How does Nuvilex compare to BioXcel Therapeutics?

Which has better earnings and valuation, PMCB or BTAI?

Is PMCB or BTAI more profitable?

Which has more volatility & risk, PMCB or BTAI?

Does the media prefer PMCB or BTAI?

Do analysts recommend PMCB or BTAI?

Do insiders & institutionals have more ownership in PMCB or BTAI?

Summary

How does Nuvilex compare to Entero Therapeutics?

Does the media favor GRDX or PMCB?

Do insiders and institutionals believe in GRDX or PMCB?

Which has more volatility & risk, GRDX or PMCB?

Do analysts rate GRDX or PMCB?

Which has preferable earnings & valuation, GRDX or PMCB?

Is GRDX or PMCB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB vs. The Competition

Nuvilex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools